<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OCH-12003020</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2012-12-28</date_registration>
      <primary_sponsor>Hematology Peking University, People's Hospital</primary_sponsor>
      <public_title>Optimizing the technology of hematopoietic stem cell transplantation: a study of optimizing treatment of acute myeloid leukemia based on the risk stratification</public_title>
      <acronym />
      <scientific_title>Optimizing the technology of hematopoietic stem cell transplantation: a study of optimizing treatment of acute myeloid leukemia based on the risk stratification</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2013-01-01</date_enrolment>
      <type_enrolment />
      <target_size>Aitologous stem cell transplantation:150;Favorable and intermediated-risk acute myeloid leu:150;High-risk acute myeloid leukemia:300;High-risk acute myeloid leukemia:300;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=6537</url>
      <study_type>Observational study</study_type>
      <study_design>Cohort study</study_design>
      <phase>II (Phase II study)</phase>
      <hc_freetext>Acute myeloid leukemia</hc_freetext>
      <i_freetext>Aitologous stem cell transplantation:Aitologous stem cell transplantation;Favorable and intermediated-risk acute myeloid leu:Chemotherapy;High-risk acute myeloid leukemia:Allogeneic hemapoietic stem cell transplantation;High-risk acute myeloid leukemia:Chemotherapy;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Huan Chen</firstname>
        <middlename />
        <lastname />
        <address>Institute of Hematology Peking University, People's Hospital, 11 Xizhimen Street South, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 10-88324952</telephone>
        <email>chenhuan@cssc.net.cn</email>
        <affiliation>Institute of Hematology Peking University, People's Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Kai-yan Liu</firstname>
        <middlename />
        <lastname />
        <address>Institute of Hematology Peking University, People's Hospital, 11 Xizhimen Street South, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 10-88324958</telephone>
        <email>liukaiyan@bimu.edu.cn</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>auto-HSCT
1. Patients with de novel AMLï¼ˆ18-60 years) in favorable and intermediate-risk group; 
2. Peripheral blood stem cell harvesting was started when included patients reached CR1 and MRD level was less than 0.1% after 1 to 2 courses of induction therapy and at least 2-4 courses of consolidation therapy including high-doses Ara-C; 
3. ECOG=0,1;
Allo-HSCT:
1. AML patients, (&lt;60 years)in high-risk group or patients in favorable and intermediate-risk group with MRD&gt;0.1% or &gt;CR1;
2. Allogenic donor is available,</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Aotu-HSCT:
1. Secondary AML, &gt;60 years old; 
2. AML 1.relapsed and refractory AML.2.ECOG &gt;=2.
3. to reach CR1 with more than 2 courses of induction; 
4. &gt;CR1 or MRD level &gt;0.1% (including RQ-PCR test ); 
5. ECOG &gt;=2.  
All0-HSCT:
1. relapsed and refractory AML;
2. ECOG &gt;=2.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>leukemia-free survival;Overall survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Association between MRD and relapse;Factors associated with prognose;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>National Public Health Grant Research Foundation (grant No. 201202017)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-10-23</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>